Anterior Uveitis Complicating Zoledronic Acid Infusion

被引：26

作者：

Colucci, Annalisa ^{[1
]}

Modorati, Giulio ^{[1
]}

Miserocchi, Elisabetta ^{[1
]}

Di Matteo, Federico ^{[1
]}

Rama, Paolo ^{[1
]}

机构：

[1] Ist Sci San Raffaele, I-20132 Milan, Italy

来源：

OCULAR IMMUNOLOGY AND INFLAMMATION | 2009年 / 17卷 / 04期

关键词：

bisphosphonates; breast cancer; uveitis; zoledronate; CANCER;

D O I：

10.1080/09273940902916111

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Zoledronic acid is the most effective treatment in patients with hypercalcemia secondary to malignancy; occasionally it can be related to ocular inflammation. We report a case of severe unilateral anterior uveitis following administration of intravenous zoledronic acid in a patient with frontal hyperostosis secondary to breast cancer. The patient developed anterior uveitis 24 hours after the administration of intravenous zoledronate. The patient was treated with topical prednisone and cycloplegic eye drops, with complete recovery after one month. This report shows that, on rare occasions, zoledronic acid can be a possible cause of acute anterior uveitis.

引用

页码：267 / 268

页数：2

共 6 条

[1] Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer
El Saghir, NS
Otrock, ZK
Bleik, JH
[J]. BMC CANCER, 2005, 5 (1)
[2] Acute retinal pigment epitheliitis associated with intravenous bisphosphonate
Gilhotra, J. S.
Gilhotra, A. K.
Holdaway, I. M.
Donaldson, M. L.
[J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2006, 90 (06) : 798 - 799
[3] Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial
Rosen, LS
Gordon, D
Kaminski, M
Howell, A
Belch, A
Mackey, J
Apffelstaedt, J
Hussein, MA
Coleman, RE
Reitsma, DJ
Chen, BL
Seaman, JJ
[J]. CANCER, 2003, 98 (08) : 1735 - 1744
[4] A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss
Santini, D.
Vincenzi, B.
Caraglia, M.
Tonini, G.
[J]. ANNALS OF ONCOLOGY, 2007, 18 (01) : 201 - U5
[5] Management of the adverse effects associated with intravenous bisphosphonates
Tanvetyanon, T.
Stiff, P. J.
[J]. ANNALS OF ONCOLOGY, 2006, 17 (06) : 897 - 907
[6] Serious ocular complications of zoledronate
Woo, T. C. S.
Joseph, D. J.
Wilkinson, R.
[J]. CLINICAL ONCOLOGY, 2006, 18 (07) : 545 - 546

← 1 →